Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Moonwalk Biosciences | South San Francisco | Series B | $70.0M | 2026-09-08 |
| Xaira Therapeutics | South San Francisco | Series A | $1.0B | 2024-04-23 |
| Quantum Circuits | New Haven | Series B | $60.0M | 2024-05-01 |
| Insitro | South San Francisco | Series C | $400.0M | 2021-03-15 |
| Pioneer Square Labs | Seattle | Series B | $15.0M | 2018-01-18 |
| Moleculent | Solna | Series A | $20.0M | 2026-04-30 |
| AIRNA | Cambridge | Series B | $155.0M | 2025-04-01 |
| Mirador Therapeutics | San Diego | Series B | $250.0M | 2026-01-12 |
8 rows of the CSV in 5 of its 18 columns.
- The 38 ARCH Venture Partners portfolio companies have raised $6.2B in total.
- 3 of them closed their most recent round in the last 12 months, $340.0M combined.
- The largest of those rounds is Mirador Therapeutics' $250.0M Series B, dated January 2026.
- The most recent is Moonwalk Biosciences' $70.0M Series B on 8 September 2026.
- Google Ventures is an investor in 5 of them, more than any other fund.
- Health care is the most common sector, with 25 companies (66%).
- 45% were founded in 2020 or later; the median founding year is 2019.
- The most common team size is 11 to 50 employees (49% of companies with a recorded size).
- 2 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
17 of 38| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco, United States | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| Moleculent | Moleculent is a biotechnology research company. | Biotech | Solna, Sweden | Series A | $20.0M | 2026-04-30 | $46.0M | ARCH Venture Partners, EIR Ventures | 11 to 50 | 2021 |
| Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego, United States | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| Gate Bioscience | Gate Bioscience is a biotechnology company developing small molecule treatments for hard-to-treat diseases. | Biotech | Brisbane, United States | Series B | $65.0M | 2025-11-13 | $125.0M | Andreessen Horowitz, Google Ventures, ARCH Venture Partners +1 | 11 to 50 | 2021 |
| Synchron | Synchron develops neuromodulation solutions for nervous system conditions previously untreatable. | Health care | Brooklyn, United States | Series D | $200.0M | 2025-11-06 | $330.0M | Alumni Ventures, Khosla Ventures, ARCH Venture Partners +1 | 101 to 250 | 2016 |
| AIRNA | AIRNA develops RNA editing technologies to create medicines for various diseases. | Biotech | Cambridge, United States | Series B | $155.0M | 2025-04-01 | $245.0M | ARCH Venture Partners, Alexandria Venture Investments, Forbion Capital Partners +2 | 51 to 100 | 2021 |
| Rhygaze | Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. | Biotech | Basel, Switzerland | Series A | $86.0M | 2025-01-10 | $97.3M | Google Ventures, F-Prime, ARCH Venture Partners +2 | 11 to 50 | 2024 |
| ArsenalBio | ArsenalBio develops programmable CAR T-cell therapies for solid tumors. | Biotech | South San Francisco, United States | Series C | $325.0M | 2024-09-04 | $630.8M | ARCH Venture Partners, Bristol-Myers Squibb, NVentures +1 | 251 to 500 | 2019 |
| Quantum Circuits | Quantum Circuits is building a full-stack quantum computer based on dual-rail qubits. | Hardware | New Haven, United States | Series B | $60.0M | 2024-05-01 | $78.0M | Sequoia Capital, F-Prime, IQT +2 | 51 to 100 | 2015 |
| Xaira Therapeutics Unicorn | Xaira Therapeutics applies artificial intelligence to drug discovery and biotechnology research. | Artificial intelligence | South San Francisco, United States | Series A | $1.0B | 2024-04-23 | $1.0B | Sequoia Capital, New Enterprise Associates, Menlo Ventures +2 | 101 to 250 | 2023 |
| Matter Neuroscience | Matter Neuroscience studies the brain's reward systems to develop treatments for mental health conditions. | Health care | Boulder, United States | Seed | $26.0M | 2024-02-27 | $26.0M | Polaris Partners, Collaborative Fund, ARCH Venture Partners | 11 to 50 | 2019 |
| Accompany Health | Accompany Health delivers in-home care to patients in underserved regions. | Health care | Bethesda, United States | Series A | $56.0M | 2024-01-30 | $56.0M | Venrock, IVP, ARCH Venture Partners +2 | 101 to 250 | 2022 |
| Basking Biosciences | Basking Biosciences commercializes technologies developed at Duke University and Ohio State University. | Biotech | Durham, United States | Series A | $55.0M | 2024-01-30 | $62.3M | Insight Partners, Rev1 Ventures, ARCH Venture Partners +1 | 1 to 10 | 2019 |
| HI-Bio | HI-Bio develops therapies for immune-mediated diseases. | Biotech | South San Francisco, United States | Series B | $95.0M | 2024-01-04 | $215.0M | ARCH Venture Partners, Alpha Wave Global, Viking Global Investors +1 | 101 to 250 | 2021 |
| Insitro Unicorn | Insitro applies machine learning and biology to drug discovery and development. | Artificial intelligence | South San Francisco, United States | Series C | $400.0M | 2021-03-15 | $643.0M | Temasek, BlackRock, ARCH Venture Partners +1 | 251 to 500 | 2018 |
| Aira | Aira provides tech-enabled services for visually impaired people worldwide. | Hardware | La Jolla, United States | Series B | $20.0M | 2018-12-21 | $35.6M | National Science Foundation, Felicis, Lux Capital +1 | 51 to 100 | 2014 |
| Pioneer Square Labs | Pioneer Square Labs is a studio that creates and launches technology startups. | Fintech | Seattle, United States | Series B | $15.0M | 2018-01-18 | $27.5M | Techstars, Menlo Ventures, True Ventures +1 | 11 to 50 | 2015 |
Table 1. ARCH Venture Partners portfolio companies: the 17 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 38.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego, United States | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 2 | Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco, United States | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| 3 | Moleculent | Moleculent is a biotechnology research company. | Biotech | Solna, Sweden | Series A | $20.0M | 2026-04-30 | $46.0M | ARCH Venture Partners, EIR Ventures | 11 to 50 | 2021 |
Table 2. ARCH Venture Partners portfolio companies: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Google Ventures | Corporate venture arm | San Francisco, United States | 5 | 13% | 1 | Moonwalk Biosciences |
| 2 | F-Prime | Venture capital firm | Cambridge, United States | 5 | 13% | ||
| 3 | Polaris Partners | Private equity firm | Boston, United States | 4 | 11% | ||
| 4 | Sequoia Capital | Venture capital firm | Menlo Park, United States | 3 | 8% | ||
| 5 | Menlo Ventures | Venture capital firm | Menlo Park, United States | 3 | 8% | ||
| 6 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 3 | 8% | ||
| 7 | Madrona | Venture capital firm | Seattle, United States | 3 | 8% | ||
| 8 | Khosla Ventures | Venture capital firm | Menlo Park, United States | 2 | 5% | 1 | Moonwalk Biosciences |
| 9 | Alpha Wave Global | Private equity firm | Miami, United States | 2 | 5% | 1 | Moonwalk Biosciences |
| 10 | Temasek | Private equity firm | Singapore | 2 | 5% | ||
| 11 | NVentures | Corporate venture arm | Santa Clara, United States | 2 | 5% | ||
| 12 | Alumni Ventures | Angel group | Manchester, United States | 2 | 5% | ||
| 13 | Future Ventures | Venture capital firm | San Francisco, United States | 1 | 3% | 1 | Moonwalk Biosciences |
| 14 | New Enterprise Associates | Venture capital firm | Menlo Park, United States | 1 | 3% | ||
| 15 | Connecticut Innovations | Government investment office | Rocky Hill, United States | 1 | 3% |
Table 3. ARCH Venture Partners portfolio companies: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 25 | 66% | $5.7B |
| Biotech | 22 | 58% | $5.4B |
| Software | 19 | 50% | $3.4B |
| Artificial intelligence | 6 | 16% | $2.4B |
| Hardware | 5 | 13% | $291.9M |
| Fintech | 2 | 5% | $75.8M |
| Commerce | 1 | 3% | $18.0M |
| Cybersecurity | 1 | 3% |
Table 4. ARCH Venture Partners portfolio companies by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
Table 5. ARCH Venture Partners portfolio companies by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United States | 36 | 95% |
| Sweden | 1 | 3% |
| Switzerland | 1 | 3% |
Table 6. ARCH Venture Partners portfolio companies by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| South San Francisco | 5 | 13% |
| Seattle | 4 | 11% |
| Cambridge | 4 | 11% |
| Brisbane | 2 | 5% |
| San Francisco | 2 | 5% |
| Boulder | 2 | 5% |
| New Haven | 1 | 3% |
| Solna | 1 | 3% |
| San Diego | 1 | 3% |
| Bethesda | 1 | 3% |
| Brooklyn | 1 | 3% |
| La Jolla | 1 | 3% |
Table 7. ARCH Venture Partners portfolio companies by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| September 2026 | 1 | 33% | $70.0M |
| April 2026 | 1 | 33% | $20.0M |
| January 2026 | 1 | 33% | $250.0M |
Table 8. ARCH Venture Partners portfolio companies: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 3 | 8% | $340.0M |
| 2025 | 5 | 13% | $706.0M |
| 2024 | 11 | 29% | $1.7B |
| 2023 | 3 | 8% | $50.0M |
| 2022 | 1 | 3% | $45.0M |
| 2021 | 1 | 3% | $400.0M |
Table 9. ARCH Venture Partners portfolio companies by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 6 | 16% |
| 2020 to 2022 | 11 | 29% |
| 2015 to 2019 | 10 | 26% |
| 2010 to 2014 | 3 | 8% |
| Before 2010 | 8 | 21% |
Table 10. ARCH Venture Partners portfolio companies by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 7 | 19% |
| 11 to 50 | 18 | 49% |
| 51 to 100 | 4 | 11% |
| 101 to 250 | 6 | 16% |
| 251 to 500 | 2 | 5% |
Table 11. ARCH Venture Partners portfolio companies by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when ARCH Venture Partners is recorded as one of its investors. On 16 November 2026 that is 38 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 17 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 38 rows: 2 have no round amount, 0 no city and 3 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many ARCH Venture Partners portfolio companies are on the list?
- 38, in the file dated 16 November 2026. 3 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 38 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.